TR200102739T2 - Aşı - Google Patents

Aşı

Info

Publication number
TR200102739T2
TR200102739T2 TR2001/02739T TR200102739T TR200102739T2 TR 200102739 T2 TR200102739 T2 TR 200102739T2 TR 2001/02739 T TR2001/02739 T TR 2001/02739T TR 200102739 T TR200102739 T TR 200102739T TR 200102739 T2 TR200102739 T2 TR 200102739T2
Authority
TR
Turkey
Prior art keywords
relates
present
vaccine
aces
mpl
Prior art date
Application number
TR2001/02739T
Other languages
English (en)
Turkish (tr)
Inventor
Capiau Carine
Deschamps Margueite
Michel Desmons Pierre
Antony Joseph Laferriere Craig
Poolman Jan
Prieels Jean-Paul
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200102739T2 publication Critical patent/TR200102739T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2001/02739T 1999-03-19 2000-03-17 Aşı TR200102739T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine

Publications (1)

Publication Number Publication Date
TR200102739T2 true TR200102739T2 (tr) 2001-12-21

Family

ID=27451884

Family Applications (3)

Application Number Title Priority Date Filing Date
TR2001/02739T TR200102739T2 (tr) 1999-03-19 2000-03-17 Aşı
TR2001/02736T TR200102736T2 (tr) 1999-03-19 2000-03-17 Aşı.
TR2001/02735T TR200102735T2 (tr) 1999-03-19 2000-03-17 Aşı.

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2001/02736T TR200102736T2 (tr) 1999-03-19 2000-03-17 Aşı.
TR2001/02735T TR200102735T2 (tr) 1999-03-19 2000-03-17 Aşı.

Country Status (32)

Country Link
US (8) US20030147922A1 (h)
EP (6) EP2277535A3 (h)
JP (4) JP2002539273A (h)
KR (3) KR100798212B1 (h)
CN (3) CN100339130C (h)
AR (3) AR022965A1 (h)
AT (3) ATE387214T1 (h)
AU (3) AU750913B2 (h)
BE (1) BE1025464I2 (h)
BR (4) BR0009166A (h)
CA (3) CA2366152A1 (h)
CY (3) CY1107561T1 (h)
CZ (3) CZ303653B6 (h)
DE (4) DE60043930D1 (h)
DK (2) DK1162999T3 (h)
ES (3) ES2275499T3 (h)
FR (1) FR10C0008I2 (h)
HK (3) HK1043728B (h)
HU (4) HUP0200664A2 (h)
IL (5) IL145044A0 (h)
LU (1) LU91652I2 (h)
MX (1) MXPA01009452A (h)
MY (2) MY125387A (h)
NL (1) NL300415I1 (h)
NO (4) NO20014322L (h)
NZ (3) NZ513841A (h)
PL (3) PL203917B1 (h)
PT (2) PT1162999E (h)
SI (2) SI1163000T1 (h)
TR (3) TR200102739T2 (h)
TW (3) TWI286938B (h)
WO (3) WO2000056358A2 (h)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ATE355375T1 (de) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
PL203917B1 (pl) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposób jej wytwarzania oraz zastosowanie
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2284182A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EA006947B1 (ru) 2001-01-23 2006-06-30 Авентис Пастер Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
WO2003094960A2 (en) * 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
AU2003274011B2 (en) * 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
MY145693A (en) 2002-11-01 2012-03-30 Glaxosmithkline Biolog Sa A method of drying without freezing or bubbling
ES2648046T3 (es) 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacárido para infecciones estafilocócicas
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PT1587537E (pt) * 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
BRPI0408094A (pt) * 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
CN1798548B (zh) 2003-06-02 2010-05-05 诺华疫苗和诊断公司 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2005237289B2 (en) 2004-04-30 2011-08-04 Glaxosmithkline Biologicals S.A. Meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP2351772B1 (en) 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
BRPI0612654B8 (pt) 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
AU2006286228A1 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI1962899T1 (sl) * 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
KR101737464B1 (ko) * 2006-01-17 2017-05-18 아르네 포르스그렌 아베 표면 노출된 헤모필루스 인플루엔자 단백질 （단백질 Ｅ ― ｐＥ）
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
EP3006041B1 (en) * 2006-03-17 2017-11-29 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
EP2004225B1 (en) 2006-03-22 2012-04-25 Novartis AG Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
TWI494124B (zh) * 2006-03-30 2015-08-01 Glaxosmithkline Biolog Sa 免疫原組合物
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20100015168A1 (en) * 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AU2007307800C1 (en) * 2006-10-10 2014-03-13 Wyeth Llc Purification of Streptococcus pneumoniae type 3 polysaccharides
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2626662T3 (es) * 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2197485B1 (en) 2007-09-12 2015-11-11 GlaxoSmithKline Biologicals SA Gas57 mutant antigens and gas57 antibodies
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
AU2009208403A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
WO2009114485A2 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
MX351810B (es) 2008-07-21 2017-10-27 Brigham & Womens Hospital Inc Metodos y composiciones que se relacionan con oligosacaridos sinteticos de beta-1, 6 glucosamina.
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
MX2011006077A (es) 2008-12-09 2011-09-01 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
EP2384120B1 (en) 2009-01-05 2019-12-11 Epitogenesis Inc. Adjuvant compositions and methods of use
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
AU2010227219B2 (en) 2009-03-24 2014-02-27 Glaxosmithkline Biologicals S.A. Adjuvanting meningococcal factor H binding protein
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
WO2011027257A2 (en) * 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2784144C (en) 2009-12-17 2017-07-11 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
NZ600978A (en) 2009-12-22 2014-08-29 Celldex Therapeutics Inc Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
JP2013530949A (ja) * 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
CN107080838A (zh) * 2010-06-04 2017-08-22 惠氏有限责任公司 疫苗制剂
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 페트르 젠나디에비치 아파린 시겔라 소네이 박테리아의 세포외 다당류, 이를 제조하는 방법, 이를 함유한 백신 및 약제 조성물
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
MX2014010011A (es) 2012-02-24 2014-09-08 Novartis Ag Proteinas y composiciones de pilus.
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2727476C2 (ru) 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
SI2844282T1 (sl) 2012-05-04 2019-08-30 Pfizer Inc. S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
ES2640320T3 (es) * 2012-10-17 2017-11-02 Glaxosmithkline Biologicals S.A. Composición inmunogénica que comprende 1 o más conjugados de sacáridos capsulares de Streptococcus pneumoniae y un componente proteico que comprende proteína E y/o PilA de Haemophilus influenzae
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
EP2996718B1 (en) 2013-05-15 2020-01-15 The Governors of the University of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN110787290B (zh) 2014-01-21 2024-06-04 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CN105934251A (zh) * 2014-01-21 2016-09-07 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
LT3110442T (lt) 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
NZ729206A (en) 2014-07-23 2022-07-01 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
PT3244917T (pt) 2015-01-15 2023-05-31 Pfizer Composições imunogénicas para utilização em vacinas pneumocócicas
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
CN107849119A (zh) 2015-07-07 2018-03-27 阿费里斯股份公司 用于治疗和预防IgE介导的疾病的疫苗
JP6994453B2 (ja) 2015-07-21 2022-01-14 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
HK1248531A1 (zh) 2015-08-25 2018-10-19 巴比塔‧阿格拉沃尔 免疫调节组合物及其使用方法
CA3000313A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
EP3405212B1 (en) 2016-01-19 2020-07-08 Pfizer Inc Cancer vaccines
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
US11191822B2 (en) * 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
MY199342A (en) 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
WO2018065625A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
AU2017339577B2 (en) 2016-10-07 2021-12-02 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 株式会社Lg化学 多价肺炎链球菌疫苗组合物
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018280272C1 (en) 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
JP2020530478A (ja) 2017-08-14 2020-10-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫応答を強化する方法
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
NZ765694A (en) 2017-12-06 2024-03-22 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019152925A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CN120535570A (zh) 2018-04-11 2025-08-26 恩特罗姆公司 用于预防和治疗癌症的抗原肽
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
JP2021522213A (ja) 2018-04-18 2021-08-30 エスケー バイオサイエンス カンパニー リミテッド ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体
MX2021000548A (es) 2018-07-19 2021-07-02 Glaxosmithkline Biologicals Sa Procesos para preparar polisacáridos en seco.
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
CN113453708B (zh) 2018-12-19 2025-02-21 默沙东有限责任公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
CA3129425A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
WO2020229964A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
AU2020325569B2 (en) 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
JP2022543281A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4357356A3 (en) 2019-11-15 2024-07-31 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
AU2021223184C1 (en) 2020-02-23 2025-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
EP4463186A1 (en) 2022-01-13 2024-11-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
CN120404993B (zh) * 2025-07-03 2025-10-03 成都迈科康生物科技有限公司 一种检测样本中mpl的方法及其相关应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0449856B1 (en) * 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
BR9405957A (pt) 1993-03-23 1995-12-12 Smithkline Beecham Biolog Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 존 더블유.로우 박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
EP0832238A1 (en) 1995-06-07 1998-04-01 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
JP2000511411A (ja) 1996-05-01 2000-09-05 ザ ロックフェラー ユニヴァーシティ 抗―肺炎球菌ワクチン用のコリン結合タンパク質
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
ATE380867T1 (de) 1997-06-03 2007-12-15 Sanofi Pasteur Ltd Lactoferrinrezeptorgen von moraxella
HUP0002475A3 (en) 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
EP1067962B1 (en) 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
JP4689044B2 (ja) * 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
PL203917B1 (pl) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposób jej wytwarzania oraz zastosowanie
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Also Published As

Publication number Publication date
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
WO2000056359A3 (en) 2001-02-01
CZ303653B6 (cs) 2013-01-30
AR022964A1 (es) 2002-09-04
US9168313B2 (en) 2015-10-27
MY125202A (en) 2006-07-31
NO2011014I2 (no) 2011-08-30
FR10C0008I2 (fr) 2012-10-26
EP1880735A3 (en) 2008-03-12
WO2000056360A3 (en) 2001-01-25
EP1776962A1 (en) 2007-04-25
WO2000056358A3 (en) 2001-01-04
CA2365296A1 (en) 2000-09-28
LU91652I9 (h) 2019-01-03
US20030147922A1 (en) 2003-08-07
EP1162998B1 (en) 2010-03-03
PL355180A1 (en) 2004-04-05
BR0009166A (pt) 2001-12-26
CN1192798C (zh) 2005-03-16
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
HU229968B1 (hu) 2015-03-30
HUP0200664A2 (en) 2002-06-29
JP2011057713A (ja) 2011-03-24
HK1043730A1 (zh) 2002-09-27
NL300415I1 (nl) 2009-12-01
JP4846906B2 (ja) 2011-12-28
CZ20013378A3 (cs) 2002-03-13
EP1163000A2 (en) 2001-12-19
KR20020000549A (ko) 2002-01-05
CY2009014I2 (el) 2010-07-28
DE122009000054I1 (de) 2009-12-31
HUP0200367A2 (en) 2002-05-29
HK1043731A1 (en) 2002-09-27
AU3813600A (en) 2000-10-09
NL300415I2 (h) 2016-12-13
CN1351501A (zh) 2002-05-29
BRPI0009163B8 (pt) 2021-05-25
KR100642044B1 (ko) 2006-11-10
HUS1500040I1 (hu) 2018-05-28
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
PL204890B1 (pl) 2010-02-26
CN1191852C (zh) 2005-03-09
TR200102736T2 (tr) 2002-04-22
JP2002540074A (ja) 2002-11-26
US20060002961A1 (en) 2006-01-05
NO20014322L (no) 2001-11-14
BRPI0009163B1 (pt) 2019-04-09
CY1107561T1 (el) 2013-03-13
CA2366314A1 (en) 2000-09-28
SI1163000T1 (sl) 2008-06-30
EP1162999B1 (en) 2006-11-29
ATE459373T1 (de) 2010-03-15
DE60032120D1 (de) 2007-01-11
FR10C0008I1 (fr) 2010-03-26
DE60038166D1 (de) 2008-04-10
MY125387A (en) 2006-07-31
TWI286938B (en) 2007-09-21
HU228499B1 (en) 2013-03-28
TWI281403B (en) 2007-05-21
NO330736B1 (no) 2011-06-27
US8926985B2 (en) 2015-01-06
JP5551579B2 (ja) 2014-07-16
BR0009163A (pt) 2001-12-26
PL203917B1 (pl) 2009-11-30
US20050031646A1 (en) 2005-02-10
AR022965A1 (es) 2002-09-04
SI1162999T1 (sl) 2007-04-30
IL145044A0 (en) 2002-06-30
CY1107390T1 (el) 2010-07-28
LU91652I2 (fr) 2010-10-13
AU750762B2 (en) 2002-07-25
CZ20013379A3 (cs) 2002-03-13
ES2339737T3 (es) 2010-05-25
CN1391481A (zh) 2003-01-15
NO20014323D0 (no) 2001-09-05
AR022963A1 (es) 2002-09-04
PL355264A1 (en) 2004-04-05
PT1162999E (pt) 2007-02-28
US20110217329A1 (en) 2011-09-08
US20060093626A1 (en) 2006-05-04
EP1163000B1 (en) 2008-02-27
CY2009014I1 (el) 2010-07-28
MXPA01009452A (es) 2002-08-06
ES2300255T3 (es) 2008-06-16
NZ513842A (en) 2004-05-28
IL145043A0 (en) 2002-06-30
AU750788B2 (en) 2002-07-25
JP2002540075A (ja) 2002-11-26
KR20020001785A (ko) 2002-01-09
WO2000056359A2 (en) 2000-09-28
DE60038166T2 (de) 2009-03-12
HK1043728B (en) 2007-06-22
CN1351503A (zh) 2002-05-29
IL145043A (en) 2007-06-17
WO2000056358A2 (en) 2000-09-28
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
EP1162999A2 (en) 2001-12-19
ATE387214T1 (de) 2008-03-15
AU750913B2 (en) 2002-08-01
IL145045A0 (en) 2002-06-30
EP2277535A2 (en) 2011-01-26
DK1163000T3 (da) 2008-04-28
WO2000056360A2 (en) 2000-09-28
CZ301445B6 (cs) 2010-03-03
CA2366314C (en) 2012-01-10
AU3430700A (en) 2000-10-09
DE60032120T2 (de) 2007-09-20
NZ513840A (en) 2004-02-27
DE60043930D1 (de) 2010-04-15
TR200102735T2 (tr) 2002-04-22
NZ513841A (en) 2001-09-28
DK1162999T3 (da) 2007-03-26
NO2011014I1 (no) 2011-09-19
US20100119544A1 (en) 2010-05-13
BR0009154A (pt) 2001-12-26
AU3291900A (en) 2000-10-09
TWI235064B (en) 2005-07-01
BE1025464I2 (h) 2019-03-06
ATE346608T1 (de) 2006-12-15
NO330532B1 (no) 2011-05-09
KR20020000785A (ko) 2002-01-05
HK1043728A1 (en) 2002-09-27
KR100798212B1 (ko) 2008-01-24
NO20014325D0 (no) 2001-09-05
IL145044A (en) 2007-03-08
NO20014322D0 (no) 2001-09-05
EP2277535A3 (en) 2011-03-09
EP1162998A2 (en) 2001-12-19
NO20014325L (no) 2001-11-14
PL355178A1 (en) 2004-04-05
HK1043731B (en) 2009-01-23
EP1880735A2 (en) 2008-01-23
JP2002539273A (ja) 2002-11-19
HUP0200373A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
TR200102739T2 (tr) Aşı
WO2007067681A3 (en) Immunostimulatory compositions and methods
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
TR200200774T2 (tr) Aşılar.
RS54349B1 (en) VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES
DE602004020189D1 (de) Adjuvante influenza-vakzine
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
GEP20074091B (en) Cripto blocking antibodies and uses thereof
EA200901340A1 (ru) Вакцина
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2010103017A3 (en) Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
EA200701766A1 (ru) Антитела против антигенов candida
WO2008008541A8 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2005026192A3 (en) Hpv cd8+ t-cell epitopes
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
WO2007104263A8 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
AU2003272188A1 (en) Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
BR0212289A (pt) Anticorpos contra caspase-8, preparação e uso do mesmo
WO2008016984A3 (en) Polysaccharide vaccine and uses thereof
WO2005012339A3 (en) Immunogenic protein and uses thereof